In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...

Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, citing a lack of inventive ...

In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...

The Indian Patent Office rejected AbbVie’s patent application for cancer drug Venetoclax (Venclexta), a decision expected to ease the entry of lower-cost generics.

Researchers analyzed the health records of more than 33,800 U.S. veterans diagnosed with non-melanoma skin cancer and found ...

CNW/ - AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now ...

Embracing the natural rhythm of one's body, akin to Ikebana's irregular beauty, can lead to acceptance and resilience. A ...

In the first Untitled Letter issued by the FDA in 2026, BeOne Medicines was critiqued for a DTC TV ad promoting its BTK ...